To: Kevin Podsiadlik who wrote (4153 ) 10/5/1999 11:47:00 AM From: DanZ Read Replies (1) | Respond to of 10293
<Probably because he knew you'd feel compelled to respond.> If this is his reason, then I'd have to add immature to his questionable character. <you're the one that's so interested in Bill's precise record> I'm not as interested in a precise record as I am in honesty. He has given me many reasons to distrust him, not the least of which is accusing respectable companies and their management of criminal activity where he is selfishly motivated by his own short position. Since he's not trustworthy, one should question his claims of making buckets of money. It isn't obvious that he is making any money, and he may well be losing overall, not to mention he may have overdrawn his portfolio with the countless trades and averaging up and down. I went through a similar drill with "Steven Sage". His "portfolio" increased from $100k to $1,000,000 overnight one day. He said he got the money from selling land. Yeah right, and I guess Bill sold some land in Fraudsville too. <I don't know the accusation to be false.> Exactly! Not to mention he hasn't even provided any reasonable evidence to support his accusation. One of the precepts that this Country is built on is innocent until proven guilty. It is very un-American to accuse someone of a crime that they haven't been found guilty of and it is wrong to condone this type of behavior. <If GUMM isn't leading investors to (unjustifiedly) believe that Zicam is a cure for the common cold, then why is that claim in the title of the GUMM thread?> GumTech isn't responsible for comments posted on a public message board by investors. I personally disagree with characterizing Zicam as a cure for the common cold, but I would agree that it is very close. If the second round of clinical studies come back positive, and the theorectical mechanism of action is proven, then I would be more inclined to say that Zicam is a cure. The company does not publicly characterize Zicam as a cure for the common cold at this time and I would agree that doing so before the second round of clinical studies are complete could be construed as hype. Contrary to the opinion of many of you on this thread, GumTech management is very conservative and very much opposed to hype.